Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
It could be that there is work/projects where they need her expertise as they prepare for funding so Dr. Heath went ahead and joined the board. Time will tell but hopefully we are close.
The only R/S will be for the uplist. The share increase is likely the conversion of preferred shares which we all knew was coming.
Was the name change discussed? I haven't followed this stock in a couple of years but am trying to do some research. I see they have been more active on Twitter.
This won't be a standard OTC R/S. They aren't doing a reverse split with convertible notes hiding in the background. There will be dilution to raise funds which will be transparent in the S1 (when it is updated). It is unfortunate the price is this low. Hopefully we move back up to the .02 to .03 range before any split but we likely need a catalyst for that to happen.
It was $6,000 of volume. You cannot agonize over every tick. You will drive yourself insane.
No way for us to know but someone picked up a lot of shares at .011 and made a nice 30% or so in a couple of weeks if they sold at .0145. Seems silly to sell with news starting to flow but can't blame someone for locking in profit.
congrats
Agreed. It is worth rereading his profile. https://curativebiotech.com/management-team
He converted on 30 March 2023 not a few days ago. It is in the report.
No he is restricted. Likely means they are getting close to financing.
Nicely done.
Interesting. I checked the NV SOS but haven't seen anything yet but it is usually a few days behind.
I took my loss on this one. Good luck to those still in it. It has a small float so certainly can move up quickly.
Has anyone had luck emailing or calling the company with questions?
That seems concerning to me. Hopefully they will have an update soon. For now, I've pulled my bids. I added a bit this morning so I still have a decent position. I hope I regret pulling those bids :)
Hi, I'm new to this stock and just picked up a starter position as I continue to research the company. Has there been an indication on the convertible debt held by Vic Devlaeminck? My concern is that it looks like those convert at .001. Has the company addressed this in anyway? Thanks.
Looks that way. Nice to see the price holding above .02. Would love to see to get above .03 before the uplist.
It has to be because it is in the articles of incorporation.
Agreed. Liquidation event is defined in the articles of inc. They essentially have to sell off the company.
Does the daily list apply if it is uplisting and will happen when it is on the NYSE?
They haven't failed the uplisitng.
I'm sure they aren't calling people out of the blue but only those that contacted Aegis to express an interest.
Where are you seeing this?
It is going to be NYSE not OTC.
Those shares are owned by insiders and part of the lock-up. They will also be subject to the reverse split. We will have less than 4M shares post split and financing.
This was well over a year ago and explained in the applicable filing.
Share based compensation decreased in 2022.
The lock-up is until 180 days after the uplist. Again, try reading the S1.
You should try reading the S1 yourself.
All things considered this isn't bad. Shows some level of confidence to have the warrant above the strike. Hopefully we get approval soon and get this uplist done. Good luck to all.
The company is not going to go under. Since the S1 was approved if they want to make changes, like adding the warrant back in they have to withdraw and refill. My guess is they institutions want their warrant. It is immensely frustrating bit as of now, I see no reason to panic.
Agreed. I suspect they got ahead of themselves removing the warrants. I haven't seen a deal like this without warrants.
At least it recovered some pre split. Probably was all for the best.
I suspect it will remain 400 to 1. That being said, I don't expect a large amount of dumping. It will be too thin. My guess is institutions buying like the long term potential but time will tell.
I agree that it will trade thin and be subject to large moves. That also makes me believe that institutions participating in the financing intend to hold opposed to immediately sell shares as it will be difficult to sell any meaningful amount of share. This view is bolstered by the lack of warrants. That is to say, when these deals happen with warrants, the institutions can sell even at a slight loss and have a close to free ride for upside.
The fact that the company negotiated the warrants out of the agreement also leads me to believe they are confident that the price will appreciate materially and if funding is needed in the future, they can do it at a higher price than exercising the warrants at the split price.
Please also recall insiders warrants will also be subject to split adjustment with many insiders needing the price to be between $40 and $80 to have value.
Also, to help ensure they are up the maximum by October 3, you'd think institutions will make sure the price is at or near .03.
After the split we will have 571,651,636/400 = 1,429,142 shares from the current O/S. The Series C will convert to approximately 612,959 shares. Add in 1,142,857 shares from the offering and we have a total of 3,184,958 shares outstanding with approximately $8,000,000 in the bank. The company has already completed the ocular tolerance study. Under the CRADA the government is taking on the vast majority of the research costs for the metformin drops. The company has been required to be in a quiet period as a result of the pending up listing. I believe it should end at the time or shortly after the up listing. It is very possible we receive news on the GLP fairly imminently.
I find it hard to believe that insiders would take the time and effort to up list to a higher exchange, add independent directors, and face additional scrutiny from the SEC as part of the up list process if this was not a legitimate business. The government support on the metformin study adds credibility. I naturally wish the share price was much higher but and the split lower but this is the circumstance we are in. The company could not wait for the share price to rise as the quite period precludes any marketing and most news. Further, we all so the unfortunate financing available without and up list. Long term, I remain confident in this company. All should evaluate the information and make their own informed choice. Personally, I added today near the low. If you are a believer in the drug, than today should have done little to change your view. Good luck to.
That is ignoring the CRADA. We will have to agree to disagree.
The float will be so small a large move will be very possible, especially if we get updates and begin to get analyst coverage. There will be around 3M shares outstanding. I don't love that it is now a 400/1 split but at this point I'm willing to give the benefit of the doubt. I do not believe they would go through the difficulty and increased scrutiny of an uplist without a belief in their pipeline and business plan.
I know you have been critical of the company and I understand your concerns but at this point I see a path to a market cap that will be 10x to 50x the market cap post split and financing and I am willing to take that risk.
Imagine if we get a 10M in volume day.